These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. The safety of regorafenib for the treatment of gastrointestinal stromal tumors. Rutkowski P; Stępniak J Expert Opin Drug Saf; 2016 Jan; 15(1):105-16. PubMed ID: 26651387 [TBL] [Abstract][Full Text] [Related]
4. Regorafenib: A Review of Its Use in Patients with Advanced Gastrointestinal Stromal Tumours. Shirley M; Keating GM Drugs; 2015 Jun; 75(9):1009-17. PubMed ID: 25998375 [TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Demetri GD; Reichardt P; Kang YK; Blay JY; Rutkowski P; Gelderblom H; Hohenberger P; Leahy M; von Mehren M; Joensuu H; Badalamenti G; Blackstein M; Le Cesne A; Schöffski P; Maki RG; Bauer S; Nguyen BB; Xu J; Nishida T; Chung J; Kappeler C; Kuss I; Laurent D; Casali PG; Lancet; 2013 Jan; 381(9863):295-302. PubMed ID: 23177515 [TBL] [Abstract][Full Text] [Related]
6. Efficacy and Safety of Regorafenib in Korean Patients with Advanced Gastrointestinal Stromal Tumor after Failure of Imatinib and Sunitinib: A Multicenter Study Based on the Management Access Program. Son MK; Ryu MH; Park JO; Im SA; Kim TY; Lee SJ; Ryoo BY; Park SR; Kang YK Cancer Res Treat; 2017 Apr; 49(2):350-357. PubMed ID: 27456941 [TBL] [Abstract][Full Text] [Related]
8. Clinical efficacy of second-generation tyrosine kinase inhibitors in imatinib-resistant gastrointestinal stromal tumors: a meta-analysis of recent clinical trials. Wu L; Zhang Z; Yao H; Liu K; Wen Y; Xiong L Drug Des Devel Ther; 2014; 8():2061-7. PubMed ID: 25378911 [TBL] [Abstract][Full Text] [Related]
9. Regorafenib: A novel tyrosine kinase inhibitor: A brief review of its therapeutic potential in the treatment of metastatic colorectal carcinoma and advanced gastrointestinal stromal tumors. Thangaraju P; Singh H; Chakrabarti A Indian J Cancer; 2015; 52(3):257-60. PubMed ID: 26905101 [TBL] [Abstract][Full Text] [Related]
10. Regorafenib for treatment of advanced gastrointestinal stromal tumors. Overton LC; Heinrich MC Expert Opin Pharmacother; 2014 Mar; 15(4):549-58. PubMed ID: 24405315 [TBL] [Abstract][Full Text] [Related]
11. A phase II trial of regorafenib in patients with metastatic and/or a unresectable gastrointestinal stromal tumor harboring secondary mutations of exon 17. Yeh CN; Chen MH; Chen YY; Yang CY; Yen CC; Tzen CY; Chen LT; Chen JS Oncotarget; 2017 Jul; 8(27):44121-44130. PubMed ID: 28487491 [TBL] [Abstract][Full Text] [Related]
12. Regorafenib for advanced gastrointestinal stromal tumors following imatinib and sunitinib treatment: a subgroup analysis evaluating Japanese patients in the phase III GRID trial. Komatsu Y; Doi T; Sawaki A; Kanda T; Yamada Y; Kuss I; Demetri GD; Nishida T Int J Clin Oncol; 2015 Oct; 20(5):905-12. PubMed ID: 25655899 [TBL] [Abstract][Full Text] [Related]
13. An update on the safety and efficacy of regorafenib in the treatment of solid cancers. Chan SL; Ma BB Expert Opin Drug Metab Toxicol; 2014 Nov; 10(11):1607-14. PubMed ID: 25316322 [TBL] [Abstract][Full Text] [Related]
14. Regorafenib. Ettrich TJ; Seufferlein T Recent Results Cancer Res; 2014; 201():185-96. PubMed ID: 24756792 [TBL] [Abstract][Full Text] [Related]
16. Regorafenib (Stivarga) for metastatic colorectal cancer and GIST. Med Lett Drugs Ther; 2013 Apr; 55(1415):e36. PubMed ID: 23836345 [No Abstract] [Full Text] [Related]
17. Long-term follow-up results of the multicenter phase II trial of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of standard tyrosine kinase inhibitor therapy. Ben-Ami E; Barysauskas CM; von Mehren M; Heinrich MC; Corless CL; Butrynski JE; Morgan JA; Wagner AJ; Choy E; Yap JT; Van den Abbeele AD; Solomon SM; Fletcher JA; Demetri GD; George S Ann Oncol; 2016 Sep; 27(9):1794-9. PubMed ID: 27371698 [TBL] [Abstract][Full Text] [Related]
18. The BRAF Status May Predict Response to Sorafenib in Gastrointestinal Stromal Tumors Resistant to Imatinib, Sunitinib, and Regorafenib: Case Series and Review of the Literature. Franck C; Rosania R; Franke S; Haybaeck J; Canbay A; Venerito M Digestion; 2019; 99(2):179-184. PubMed ID: 30179868 [TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of imatinib and sunitinib: a multicenter phase II trial. George S; Wang Q; Heinrich MC; Corless CL; Zhu M; Butrynski JE; Morgan JA; Wagner AJ; Choy E; Tap WD; Yap JT; Van den Abbeele AD; Manola JB; Solomon SM; Fletcher JA; von Mehren M; Demetri GD J Clin Oncol; 2012 Jul; 30(19):2401-7. PubMed ID: 22614970 [TBL] [Abstract][Full Text] [Related]
20. Systemic therapy of advanced/metastatic gastrointestinal stromal tumors: an update on progress beyond imatinib, sunitinib, and regorafenib. Mohammadi M; Gelderblom H Expert Opin Investig Drugs; 2021 Feb; 30(2):143-152. PubMed ID: 33252274 [No Abstract] [Full Text] [Related] [Next] [New Search]